LPA Receptor
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN26691 | TAK-615 | 1664335-55-0 | TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (Kd high affinity of 1.7 nM and Kd low affinity of 14.5 nM)[1]. |
CSN23706 | 1-Oleoyl lysophosphatidic acid sodium | 325465-93-8 | Lysophosphatidic Acid is a water-soluble endogenous phospholipid in serum acting as ligand activator for EDG-2 and EDG-4 (LPA) receptors. |
CSN16828 | LPA2 antagonist 1 | 1017606-66-4 | LPA2 antagonist 1 is an LPA2 antagonist with an IC50 of 17 nM |
CSN12695 | Ki16425 | 355025-24-0 | Ki16425 is a competitive potent and reversible antagonist to LPA1 LPA2 and LPA3 with Ki of 034 M 65 M and 093 M respectively shows no activity at LPA4 LPA5 LPA6 |
CSN18649 | Ki16198 | 355025-13-7 | Ki16198 is the methyl ester of Ki16425 which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 034 M and 093 M respectively shows weaker inhibition for LPA2 no activity at LPA4 LPA5 LPA6 |
CSN33164 | AS2717638 | 2148339-28-8 | AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia. |
CSN13766 | AM966 | 1228690-19-4 | AM966 is a high affinity, selective, oral LPA1 (lysophosphatidic acid receptor, IC5017 nM) antagonist, with selectivity for this receptor over the other LPA receptors. |